Geron Corporation (0IV3.L)
USD 1.36
(-8.26%)
USD 1.36
(-8.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 146.12 Million USD | 32.15% |
| 2022 | 110.57 Million USD | 11.0% |
| 2021 | 99.61 Million USD | 66.64% |
| 2020 | 59.78 Million USD | 96.89% |
| 2019 | 30.36 Million USD | 302.09% |
| 2018 | 7.55 Million USD | 15.88% |
| 2017 | 6.51 Million USD | -17.19% |
| 2016 | 7.86 Million USD | 18.62% |
| 2015 | 6.63 Million USD | -84.13% |
| 2014 | 41.79 Million USD | 450.93% |
| 2013 | 7.58 Million USD | -46.37% |
| 2012 | 14.14 Million USD | 5.24% |
| 2011 | 13.44 Million USD | -67.09% |
| 2010 | 40.84 Million USD | 423.37% |
| 2009 | 7.8 Million USD | 0.54% |
| 2008 | 7.76 Million USD | -41.29% |
| 2007 | 13.22 Million USD | -71.8% |
| 2006 | 46.88 Million USD | 344.88% |
| 2005 | 10.53 Million USD | 7.42% |
| 2004 | 9.81 Million USD | -16.8% |
| 2003 | 11.79 Million USD | -61.88% |
| 2002 | 30.92 Million USD | -10.84% |
| 2001 | 34.68 Million USD | -30.78% |
| 2000 | 50.11 Million USD | 33.63% |
| 1999 | 37.5 Million USD | 220.51% |
| 1998 | 11.7 Million USD | 134.0% |
| 1997 | 5 Million USD | -3.85% |
| 1996 | 5.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 137.2 Million USD | -6.1% |
| 2024 Q2 | 142.7 Million USD | 4.01% |
| 2023 Q1 | 98.82 Million USD | -10.63% |
| 2023 Q4 | 146.12 Million USD | 19.38% |
| 2023 Q3 | 122.4 Million USD | 4.74% |
| 2023 FY | 146.12 Million USD | 32.15% |
| 2023 Q2 | 116.86 Million USD | 18.26% |
| 2022 FY | 110.57 Million USD | 11.0% |
| 2022 Q4 | 110.57 Million USD | -11.14% |
| 2022 Q1 | 100.93 Million USD | 1.32% |
| 2022 Q2 | 96.11 Million USD | -4.78% |
| 2022 Q3 | 124.43 Million USD | 29.47% |
| 2021 Q4 | 99.61 Million USD | 28.47% |
| 2021 FY | 99.61 Million USD | 66.64% |
| 2021 Q1 | 57.44 Million USD | -3.91% |
| 2021 Q2 | 75.96 Million USD | 32.24% |
| 2021 Q3 | 77.54 Million USD | 2.07% |
| 2020 FY | 59.78 Million USD | 96.89% |
| 2020 Q4 | 59.78 Million USD | 12.88% |
| 2020 Q1 | 22.07 Million USD | -27.29% |
| 2020 Q2 | 24.13 Million USD | 9.32% |
| 2020 Q3 | 52.96 Million USD | 119.45% |
| 2019 Q4 | 30.36 Million USD | 155.96% |
| 2019 FY | 30.36 Million USD | 302.09% |
| 2019 Q1 | 6.25 Million USD | -17.19% |
| 2019 Q2 | 9.18 Million USD | 46.83% |
| 2019 Q3 | 11.86 Million USD | 29.2% |
| 2018 Q4 | 7.55 Million USD | 69.04% |
| 2018 FY | 7.55 Million USD | 15.88% |
| 2018 Q3 | 4.46 Million USD | -8.93% |
| 2018 Q2 | 4.9 Million USD | 11.86% |
| 2018 Q1 | 4.38 Million USD | -32.7% |
| 2017 Q3 | 5.97 Million USD | -47.05% |
| 2017 Q4 | 6.51 Million USD | 9.15% |
| 2017 FY | 6.51 Million USD | -17.19% |
| 2017 Q1 | 11.59 Million USD | 47.36% |
| 2017 Q2 | 11.27 Million USD | -2.78% |
| 2016 Q2 | 7.11 Million USD | 6.8% |
| 2016 Q4 | 7.86 Million USD | 7.51% |
| 2016 Q1 | 6.65 Million USD | 0.36% |
| 2016 Q3 | 7.31 Million USD | 2.93% |
| 2016 FY | 7.86 Million USD | 18.62% |
| 2015 Q1 | 40.63 Million USD | -2.79% |
| 2015 Q4 | 6.63 Million USD | 8.31% |
| 2015 FY | 6.63 Million USD | -84.13% |
| 2015 Q3 | 6.12 Million USD | -84.96% |
| 2015 Q2 | 40.72 Million USD | 0.23% |
| 2014 Q1 | 4.51 Million USD | -40.48% |
| 2014 FY | 41.79 Million USD | 450.93% |
| 2014 Q2 | 4.75 Million USD | 5.31% |
| 2014 Q4 | 41.79 Million USD | 491.3% |
| 2014 Q3 | 7.06 Million USD | 48.63% |
| 2013 Q4 | 7.58 Million USD | 10.97% |
| 2013 Q1 | 6.79 Million USD | -51.99% |
| 2013 FY | 7.58 Million USD | -46.37% |
| 2013 Q2 | 5 Million USD | -26.34% |
| 2013 Q3 | 6.83 Million USD | 36.63% |
| 2012 FY | 14.14 Million USD | 5.24% |
| 2012 Q4 | 14.14 Million USD | 25.69% |
| 2012 Q3 | 11.25 Million USD | -6.14% |
| 2012 Q2 | 11.99 Million USD | 16.72% |
| 2012 Q1 | 10.27 Million USD | -23.58% |
| 2011 FY | 13.44 Million USD | -67.09% |
| 2011 Q1 | 9.36 Million USD | -77.08% |
| 2011 Q2 | 9.27 Million USD | -0.99% |
| 2011 Q3 | 13.19 Million USD | 42.36% |
| 2011 Q4 | 13.44 Million USD | 1.87% |
| 2010 Q1 | 6.98 Million USD | -10.57% |
| 2010 FY | 40.84 Million USD | 423.37% |
| 2010 Q4 | 40.84 Million USD | 435.72% |
| 2010 Q3 | 7.62 Million USD | 11.92% |
| 2010 Q2 | 6.81 Million USD | -2.39% |
| 2009 Q2 | 10.41 Million USD | 34.22% |
| 2009 FY | 7.8 Million USD | 0.54% |
| 2009 Q4 | 7.8 Million USD | -21.03% |
| 2009 Q3 | 9.88 Million USD | -5.09% |
| 2009 Q1 | 7.75 Million USD | -0.05% |
| 2008 Q4 | 7.76 Million USD | -9.8% |
| 2008 FY | 7.76 Million USD | -41.29% |
| 2008 Q1 | 8.84 Million USD | -33.1% |
| 2008 Q2 | 8.64 Million USD | -2.28% |
| 2008 Q3 | 8.6 Million USD | -0.44% |
| 2007 FY | 13.22 Million USD | -71.8% |
| 2007 Q4 | 13.22 Million USD | 6.07% |
| 2007 Q3 | 12.46 Million USD | -17.91% |
| 2007 Q2 | 15.18 Million USD | 37.86% |
| 2007 Q1 | 11.01 Million USD | -76.51% |
| 2006 Q4 | 46.88 Million USD | 664.41% |
| 2006 Q3 | 6.13 Million USD | -1.86% |
| 2006 FY | 46.88 Million USD | 344.88% |
| 2006 Q1 | 7.81 Million USD | -25.86% |
| 2006 Q2 | 6.24 Million USD | -20.02% |
| 2005 FY | 10.53 Million USD | 7.42% |
| 2005 Q4 | 10.53 Million USD | 0.93% |
| 2005 Q3 | 10.44 Million USD | 71.98% |
| 2005 Q2 | 6.07 Million USD | -0.96% |
| 2005 Q1 | 6.13 Million USD | -37.51% |
| 2004 Q1 | 8.22 Million USD | -30.28% |
| 2004 Q3 | 8.46 Million USD | -15.18% |
| 2004 FY | 9.81 Million USD | -16.8% |
| 2004 Q4 | 9.81 Million USD | 15.85% |
| 2004 Q2 | 9.98 Million USD | 21.43% |
| 2003 FY | 11.79 Million USD | -61.88% |
| 2003 Q1 | 29.25 Million USD | -5.42% |
| 2003 Q3 | 10.38 Million USD | -9.8% |
| 2003 Q2 | 11.51 Million USD | -60.63% |
| 2003 Q4 | 11.79 Million USD | 13.51% |
| 2002 FY | 30.92 Million USD | -10.84% |
| 2002 Q1 | 33.64 Million USD | -3.0% |
| 2002 Q4 | 30.92 Million USD | -2.36% |
| 2002 Q3 | 31.67 Million USD | -3.45% |
| 2002 Q2 | 32.8 Million USD | -2.5% |
| 2001 FY | 34.68 Million USD | -30.78% |
| 2001 Q2 | 49.79 Million USD | 1.96% |
| 2001 Q1 | 48.84 Million USD | -2.54% |
| 2001 Q3 | 49.52 Million USD | -0.55% |
| 2001 Q4 | 34.68 Million USD | -29.95% |
| 2000 FY | 50.11 Million USD | 33.63% |
| 2000 Q3 | 52.74 Million USD | 0.17% |
| 2000 Q2 | 52.65 Million USD | 82.94% |
| 2000 Q1 | 28.78 Million USD | -23.25% |
| 2000 Q4 | 50.11 Million USD | -4.98% |
| 1999 Q2 | 33.5 Million USD | 168.0% |
| 1999 Q1 | 12.5 Million USD | 6.84% |
| 1999 FY | 37.5 Million USD | 220.51% |
| 1999 Q4 | 37.5 Million USD | -12.59% |
| 1999 Q3 | 42.9 Million USD | 28.06% |
| 1998 Q1 | 3.4 Million USD | -32.0% |
| 1998 Q2 | 4.4 Million USD | 29.41% |
| 1998 Q4 | 11.7 Million USD | 192.5% |
| 1998 FY | 11.7 Million USD | 134.0% |
| 1998 Q3 | 4 Million USD | -9.09% |
| 1997 Q2 | 7 Million USD | 59.09% |
| 1997 Q1 | 4.4 Million USD | -15.38% |
| 1997 FY | 5 Million USD | -3.85% |
| 1997 Q4 | 5 Million USD | -15.25% |
| 1997 Q3 | 5.9 Million USD | -15.71% |
| 1996 Q3 | 5.2 Million USD | -14.75% |
| 1996 Q4 | 5.2 Million USD | 0.0% |
| 1996 Q1 | 3.4 Million USD | 0.0% |
| 1996 FY | 5.2 Million USD | 0.0% |
| 1996 Q2 | 6.1 Million USD | 79.41% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 76.583% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -15.883% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 76.344% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 44.803% |
| bluebird bio, Inc. | 424.62 Million USD | 65.587% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -112.521% |
| Imunon, Inc. | 8.53 Million USD | -1613.009% |
| Editas Medicine, Inc. | 150.05 Million USD | 2.618% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.29% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 95.831% |
| Myriad Genetics, Inc. | 312.9 Million USD | 53.299% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 85.665% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 70.023% |
| Verastem, Inc. | 71.18 Million USD | -105.278% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.788% |
| Waters Corporation | 3.47 Billion USD | 95.797% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.718% |
| Biogen Inc. | 12.04 Billion USD | 98.787% |
| Nektar Therapeutics | 267.04 Million USD | 45.28% |
| Perrigo Company plc | 6.04 Billion USD | 97.581% |
| Dynavax Technologies Corporation | 375.02 Million USD | 61.035% |
| Illumina, Inc. | 4.36 Billion USD | 96.653% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -315.404% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 25.346% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 43.026% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -291.845% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.269% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -77.268% |
| Evolus, Inc. | 209.68 Million USD | 30.312% |
| Adicet Bio, Inc. | 37.12 Million USD | -293.661% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -263.265% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.944% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 77.886% |
| FibroGen, Inc. | 585.72 Million USD | 75.052% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 97.029% |
| OPKO Health, Inc. | 622.47 Million USD | 76.525% |
| Homology Medicines, Inc. | 118.53 Million USD | -23.28% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.392% |
| Exelixis, Inc. | 678.44 Million USD | 78.461% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -628.05% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1065.845% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 41.738% |
| Zoetis Inc. | 9.29 Billion USD | 98.428% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 63.216% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -197.151% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.162% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -201.635% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.387% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 93.925% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -27.275% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 91.141% |
| Blueprint Medicines Corporation | 918.64 Million USD | 84.093% |
| Insmed Incorporated | 1.66 Billion USD | 91.206% |
| TG Therapeutics, Inc. | 169.08 Million USD | 13.578% |
| Incyte Corporation | 1.59 Billion USD | 90.823% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 87.675% |